Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia》.pdf

Journal of Clinical Lipidology (2009) 3, 332–340 Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia Michael H. Davidson, MD*, Kevin C. Maki, PhD, Harold Bays, MD, Roderick Carter, MD, MSc†, Christie M. Ballantyne, MD Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60654, USA (Dr. Davidson); The University of Chicago Pritzker School of Medicine, Chicago, IL, USA (Dr. Davidson); Provident Clinical Research, Bloomington, IN, USA (Dr. Maki); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr. Bays); Reliant Pharmaceuticals, Inc. (a subsidiary of GlaxoSmithKline), Liberty Corner, NJ, USA (Dr. Carter); and Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Baylor College of Medicine, Houston, TX, USA (Dr. Ballantyne) KEYWORDS: BACKGROUND: Prescription omega-3-acid ethyl esters (P-OM3) often are used for hypertriglyceri- High-density lipoprotein; demic patients receiving statin therapy who have residual increases in atherogenic lipoprotein lipid Hypertriglyceridemia; levels. To date, limited information has been published regarding the effects of omega-3 fatty acid Low-density lipoprotein; consumption on lipoprotein particle concentrations. Prescription omega-3- OBJECTIVE: We evaluated the effects of adding P-OM3 4 g/d to an ongoing regimen of simvastatin acid ethyl esters; 40 mg/d on lipoprotein particles (P) in subjects with hypertriglyceridemia. Simvastatin METHODS: Data were analyzed from the multicenter, randomized, double-blind, placebo-controlled Combination of Prescription Omega